Localization of distinct F2-isoprostanes in human atherosclerotic lesions

Journal of Clinical Investigation

Volumn 100, Issue 8, 1997, Pages 2028-2034

  Praticò, Domenico ^a   Iuliano, Luigi ^b   Mauriello, Alessandro ^c   Spagnoli, Luigi ^c   Lawson, John A ^a   Maclouf, Jacques ^d   Violi, Francesco ^b   FitzGerald, Garret A ^a,e  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d INSERM   (France)

^e Stellar Chance Laboratories   (United States)

Author keywords

Atherosclerosis; Isoprostanes; Lipid peroxidation; Oxidative stress

Indexed keywords

ALPHA ACTIN; ARACHIDONIC ACID; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN F2 ALPHA DERIVATIVE; 8 EPI PROSTAGLANDIN F2ALPHA; 8-EPI-PROSTAGLANDIN F2ALPHA; CD68 ANTIGEN, HUMAN; DIFFERENTIATION ANTIGEN; DRUG DERIVATIVE; LEUKOCYTE ANTIGEN; PHOSPHOLIPID; PROSTAGLANDIN F2 ALPHA;

ARACHIDONIC ACID METABOLISM; ARTICLE; ATHEROSCLEROSIS; HUMAN; IMMUNOHISTOCHEMISTRY; LIPID PEROXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTAGLANDIN BLOOD LEVEL; ADULT; AGED; AORTA; ARTERIOSCLEROSIS; ARTERY; CAROTID ARTERY; CHEMISTRY; FOAM CELL; ISOMERISM; MALE; MIDDLE AGED; PATHOLOGY; PULMONARY ARTERY;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; AORTA; ARTERIES; ARTERIOSCLEROSIS; CAROTID ARTERIES; DINOPROST; FOAM CELLS; HUMANS; ISOMERISM; LIPID PEROXIDATION; MALE; MIDDLE AGED; OXIDATIVE STRESS; PHOSPHOLIPIDS; PULMONARY ARTERY;

EID: 0030611766     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119735     Document Type: Article

References (54)

1. Steinberg, D., S. Parthasarathy, T.E. Carew, J.C. Khoo, and J.L. Witztum. 1989. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 320:915-924.
2. Witztum, J.L. 1994. The oxidation hypothesis of atherosclerosis. Lancet. 334:793-795.
3. Yla-Herttuala, S., B.A. Lipton, M.E. Rosenfeld, T. Sarkioja, T. Yoshimura, E.J. Leonard, J.L. Witztum, and D. Steinberg. 1991. Macrophages and smooth muscle cells express lipoprotein lipase in human and rabbit atherosclerotic lesions. Proc. Natl. Acad. Sci. USA. 88:5252-5256.
4. Berliner, J.A., M.C. Territo, A. Sevanian, S. Ramin, J.A. Kim, B. Barnshad, M. Esterson, and A.M. Fogelmann. 1990. Minimally modified low density lipoprotein stimulates monocyte-endothelial interactions. J. Clin. Invest. 85: 1260-1266.
5. Weiss, J.R., R.E. Pitas, B.D. Wilson, and G.M. Rodgers. 1991. Oxidized low-density lipoprotein increases cultured human endothelial cell tissue factor activity and reduces protein C activation. FASEB (Fed. Am. Soc. Exp. Biol.) J. 5:2459-2465.
6. 2. Arterioscler. Thromb. Vasc. Biol. 5:1131-1138.
7. Mehta, A., B. Yang, S. Khan, J.B. Hendricks, C. Stephen, and J.L. Mehta. 1995. Oxidized low-density lipoproteins facilitate leukocyte adhesion to aortic intima without affecting endothelium-dependent relaxation. Arterioscler. Thromb. Vasc. Biol. 15:2076-2083.
8. Lehr, H.A., M. Becker, S.L. Marklund, C. Hubner, K.E. Arfors, A. Kohlschutter, and K. Messmer. 1992. Superoxide-dependent stimulation of leukocyte adhesion by oxidatively modified LDL in vivo. Arterioscler. Thromb. Vasc. Biol. 12:824-829.
9. Brown, M.S., and J.L. Goldstein. 1983. Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Annu. Rev. Bioehem. 12:223-261.
10. Arai, H., T. Kita, M. Yokade, S. Narumiya, and C. Kawai. 1989. Multiple receptors for modified low density lipoproteins in mouse peritoneal macrophages: different uptake mechanisms for acetylated and oxidized low density lipoproteins. Biochem. Biophys. Res Commun. 159:1375-1382.
11. Sparrow, C.P., S. Parthasarathy, and D. Steinberg. 1989. A macrophage receptor that recognizes oxidized low density lipoprotein hul not acetylated low density lipoprotein. J. Biol. Chem. 64:2599-2604.
12. Roher, L., M. Freeman, T. Kodama, M. Penman, and M. Krieger. 1990. Coiled-coil fibrous domains mediate ligand binding by macrophage scavenger receptor type II. Nature (Lond.). 343:570-572.
13. Salonen, J.T., S. Yla-Herttuala, R. Yamamoto, S. Butler, H. Korpela, R. Salonen K. Nyyssonen, W. Palinski, and J.L. Witztum. 1992. Autoantibody against oxidized LDL and progression of carotid atherosclerosis. Lancet. 339: 883-887.
14. Gutteridge, J.M.C. 1986. Aspects to consider when detecting and measuring lipid peroxidation. Free Radical Res. Commun. 1:173-184.
15. Gutteridge, J.M.C., and B. Halliwell. 1990. The measurement and mechanism of lipid peroxidation in biological systems. Trends Biochem. Sci. 15:129-135.
16. Lenz, M.L., H. Hughes, J.R. Mitchell, D.P. Via, J.R. Guyton, A.A. Taylor, A.M. Gotto, and C.V. Smith. 1990. Lipid hydroperoxy and hydroxy derivatives in copper-catalyzed oxidation of low density lipoprotein. J. Lipid Res. 31: 1043-1050.
17. O'Connor, D.E., E.D. Mihelich, and M.C. Coleman. 1984. Stereochemical course of the autoxidative cyclization of lipid hydroperoxides to prostaglandin-like bicyclo endoperoxides. J. Am. Chem. Soc. 106:3577-3584.
18. 2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc. Natl. Acad. Sci. USA. 87:9383-9387.
19. 2α, is formed in vivo. Biochim. Biophys. Acta. 1210:244-248.
20. 2-isoprostanes) in plasma and low density lipoprotein exposed to oxidative stress in vitro. J. Clin. Invest. 93:998-1004.
21. Reilly, M., N. Delanty, J.A. Lawson, and G.A. FitzGerald. 1996. Modulation of oxidant stress in vivo in chronic cigarette smokers. Circulation. 94:19-25.
22. 2α generation during coronary reperfusion: a potential quantitative marker of oxidant stress in vivo. Circulation. 95:2492-2499.
23. Loft, S., A. Astrup, B. Buemann, and H.E. Poulsen. 1994. Oxidative DNA damage correlates with oxygen consumption in humans. FASEB (Fed. Am. Soc. Exp. Biol) J. 8:534-537.
24. Bolli, R., M. Zughaib, X.Y. Li, J.Z. Sun, J.F. Triana, and P.B. McCay. 1995. Recurrent ischemia in the canine heart causes recurrent bursts of free radical production that have a cumulative effect on contractile function. J. Clin. Invest. 96:1066-1084.
25. 2α by human monocytes. Discriminate production by reactive oxygen species and prostaglandin endoperoxide synthase-2. J. Biol. Chem. 271:8919-8924.
26. 2α-I and its identification in biological fluids. Tetrahedron Lett. 37:4849-4852.
27. 2-isoprostanes produced by non-cyclooxygenase free radical-catalyzed mechanism. Methods Enzymol. 233:163-174.
28. Morrison, W.K. 1964. A fast, simple and reliable method for the microdetermination of phosphorus in biological materials. Anal. Biochem. 7:218-224.
29. 2α excretion in man. J. Pharmacol. Exp. Ther. 275:94-100.
30. Pulford, K.A.F., E.M. Rigney, K.J. Micklem, M. Jones, W.P. Stross, K.C, Gatter and D.Y. Mason. 1989. KP1: a new monoclonal antibody that detects a monocyte/macrophage associated antigen in routinely processed tissue sections. J. Clin. Pathol. 42:14-21.
31. Skalli, O., P. Ropraz, A. Trzeciak, G. Benzonana, D. Gillesen, and G. Gabbiani. 1986. A monoclonal antibody against alpha-smooth muscle actin: a new probe for smooth muscle differentiation. J. Cell Biol. 103:2787-2796.
32. 2 receptors. J. Clin. Invest. 90:136-141.
33. 2α, in rabbit lung in situ. Am. J. Physiol. 263:H660-H663.
34. 2-isoprostane receptors on rat vascular smooth muscle cells. Am. J. Physiol. 264:C1619-C1624.
35. 2α, J. Pharmacol. Exp. Ther. 281:957-964.
36. 2α is not mediated by thromboxane receptor isoforms. J. Biol. Chem. 271:14916-14924.
37. 2α. J. Biol. Chem. 270:9800-9808.
38. 2-isoprostane formation. Br. J. Pharmacol. 118:1285-1293.
39. 2-isoprostanes as non-invasive indices of oxidanl stress in vivo. Circulation. In press.
40. Craig, W.Y., S.E. Poulin, G.E. Palomaki, L.M. Neveux, R.F. Ritchie, and T.B. Ledue. 1995. Oxidation-related analytes and lipid and lipoprotein concentrations in healthy subjects. Arterioscler. Thromb. Vasc. Biol. 15:733-739.
41. Chen, M.F., H.C. Hsu, and Y.T. Lee. 1994. Effects of acute exercise on the chances of lipid profiles and peroxides, prostanoids, and platelet activation in hypercholesterolemic patients before and after treatment. Prostaglandins. 48:157-174.
42. Holvoet, P., G. Perez, Z. Zhao. E. Brouwers, and D. Collen. 1995. Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease. J. Clin. Invest. 95:2611-2619.
43. 2-isoprostanes. J. Nutr. 124:810-816.
44. 2-isoprostanes) in carbon-tetrachloride hepatotoxicity. An animal model of lipid peroxidation. J. Clin. Invest. 90:2502-2507.
45. 2α: specific analysis of an isoeicosanoid as an index of oxidant stress in vivo. Br. J. Clin. Pharmacol. 42:15-19.
46. 2α in acute coronary angioplasty: evidence for oxidant stress during coronary reperfusion in humans. Circulation. In press.
47. 2α in familial hypercholesterolemia: evidence of oxidative stress. Circulation. 94:3727. (Abstr.)
48. Brown, D.L., M.S. Hibbs, M. Kearney, C. Loushin, and J.M. Isner. 1995. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. Circulation. 91: 2125-2131.
49. Yla-Herttuala, S., W. Palinski, M.E. Rosenfeld. S. Parthasarathy, T.E. Carew, S. Butler, J.L. Witztum, and D. Steinherg. 1989. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J. Clin. Invest. 84:1086-1095.
50. Rosenfeld, M.E., W. Palinski, S. Yla-Herttuala, S. Butler, and J.L. Witztum. 1990. Distribution of oxidation specific lipid-protein adducts and apolipo-protein-B in atherosclerosis lesions of varying severity from WHHL rabbits. Arteriosclerosis. 10:336-349.
51. Ross, R. 1993. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature (Lond.). 362:801-809.
52. Knox, J.B., G.K. Sukhova, A.D. Whittemore, and P. Libby, 1997. Evidence for altered balance between matrix metalloproteinases and their inhibitors in human aortic diseases. Circulation. 95:205-212.
53. Li, Q., and M.K. Cathcart. 1994. Protein kinase C activity is required for lipid oxidation of low density lipoprotein by activated human monocytes. J. Biol. Chem. 269:17508-17515.
54. Heinecke, J. W., H. Rosen, and A. Chair. 1984. Iron and copper promote modification of low density lipoprotein by human arterial smooth muscle cells in culture. J. Clin. Invest. 4:1890-1894.